GlassScriptPhysician profile
Yasmin Islam
NPI 1225558455
$4,570.81
in general payments reported to CMS, 2019-2025
21 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $176 · 2021: $646 · 2022: $883 · 2023: $852 · 2024: $945 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $1,137.37 | 2019-2024 | Omni Surgical System |
| Abbvie INC. | $871.88 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $509.37 | 2020-2022 | |
| Glaukos Corporation | $469.45 | 2019-2022 | |
| Alcon Vision LLC | $404.18 | 2019-2025 | Centurion, Hydrus Microstent, Unity |
| Bausch & Lomb Americas INC. | $293.15 | 2022-2025 | Ic-8 Apthera Iol, Envista Mx60 Iol, Vyzulta |
| Mallinckrodt Enterprises LLC | $237.61 | 2019 | |
| New World Medical,INC. | $178.32 | 2021-2023 | |
| Spark Therapeutics, INC. | $85.82 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $80.02 | 2022-2023 | Acuvue |
| Dompe US, INC. | $52.25 | 2025 | Oxervate |
| Amgen INC. | $48.06 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $43.85 | 2025 | Acthar |
| Genentech USA, INC. | $28.23 | 2025 | Vabysmo |
| Astellas Pharma US INC | $24.96 | 2024 | Izervay |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $20.45 | 2023 | |
| Harrow Eye, LLC | $20.41 | 2024 | Vevye |
| Apellis Pharmaceuticals, INC. | $18.28 | 2025 | Syfovre |
| Sun Pharmaceutical Industries INC. | $17.29 | 2024 | |
| Alimera Sciences, INC. | $15.90 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $13.96 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.